,

Recombinant Human Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)-VLPs (Active)

Recombinant Human Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)-VLPs (Active) — Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake. Purity /.

SKU: BCACP-000546 Categories: ,
Product SKUBCACP-000546
Product DescriptionRecombinant Human Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)-VLPs protein is expressed from Mammalian cell with C-terminal 10xHis-tagged. It contains 1-492aa. [Accession | P11166].
Uniprot No.P11166
Gene NamesSLC2A1
Purity/
Expression SystemMammalian cell
Expression Region1-492aa
SpeciesHomo sapiens (Human)
Tag InfoC-terminal 10xHis-tagged
Molecular weight55.5 kDa
ActivityMeasured by its binding ability in a functional ELISA. Immobilized Cricetulus griseus HSPA5 at 2 μg/mL can bind Anti-HSPA5 recombinant antibody . The EC50 is 1.884-2.205 ng/mL.
BufferLyophilized from a 0.2 μm filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0
StorageStore at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Alternative NamesSolute carrier family 2, facilitated glucose transporter member 1; Glucose transporter type 1, erythrocyte/brain; HepG2 glucose transporter; SLC2A1; GLUT1

Function

Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses. Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative transport of glucose into the brain.

Biological Context

Subcellular Location: Cell membrane (Multi-pass membrane protein); Melanosome; Photoreceptor inner segment
Tissue Specificity: Detected in erythrocytes (at protein level). Expressed at variable levels in many human tissues
Disease Association: GLUT1 deficiency syndrome 1 (GLUT1DS1) : A neurologic disorder showing wide phenotypic variability. The most severe 'classic' phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor incoordination, and spasticity. Onset of seizures, usually characterized by apneic episodes, staring spells, and episodic eye movements, occurs within the first 4 months of life. Other paroxysmal findings include intermittent ataxia, confusion, lethargy, sleep disturbance, and headache. Varying degrees of cognitive impairment can occur, ranging from learning disabilities to severe intellectual disability. [The disease is caused by variants affecting the gene represented in this entry] | GLUT1 deficiency syndrome 2 (GLUT1DS2) : A clinically variable disorder characterized primarily by onset in childhood of paroxysmal exercise-induced dyskinesia. The dyskinesia involves transient abnormal involuntary movements, such as dystonia and choreoathetosis, induced by exercise or exertion, and affecting the exercised limbs. Some patients may also have epilepsy, most commonly childhood absence epilepsy. Mild intellectual disability may also occur. In some patients involuntary exertion-induced dystonic, choreoathetotic, and ballistic movements may be associated with macrocytic hemolytic anemia. [The disease is caused by variants affecting the gene represented in this entry] | Epilepsy, idiopathic generalized 12 (EIG12) : A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain. Seizure types include juvenile myoclonic seizures, absence seizures, and generalized tonic-clonic seizures. In some EIG12 patients seizures may remit with age. [Disease susceptibility is associated with variants affecting the gene represented in this entry] | Dystonia 9 (DYT9) : An autosomal dominant neurologic disorder characterized by childhood onset of paroxysmal choreoathetosis and progressive spastic paraplegia. Most patients show some degree of cognitive impairment. Other variable features may include seizures, migraine headaches, and ataxia. [The disease is caused by variants affecting the gene represented in this entry] | Stomatin-deficient cryohydrocytosis with neurologic defects (SDCHCN) : A rare form of stomatocytosis characterized by episodic hemolytic anemia, cold-induced red cells cation leak, erratic hyperkalemia, neonatal hyperbilirubinemia, hepatosplenomegaly, cataracts, seizures, intellectual disability, and movement disorder. [The disease is caused by variants affecting the gene represented in this entry]
Pathway: Carbohydrate degradation

Product Specifications

Recombinant Human Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)-VLPs (Active) is a recombinant protein from Homo sapiens (Human), expressed in Mammalian cell, covering amino acids 1-492aa, with C-terminal 10xHis-tagged tag, molecular weight 55.5 kDa, purity /. Suitable for ELISA and Western Blot applications.

SDS-PAGE: Single band at expected molecular weight confirming purity.

ELISA: Suitable as coating antigen or detection standard.

Western Blot: Compatible with standard Western Blot protocols.

Protein Interaction: Validated for SPR (Surface Plasmon Resonance) and BLI (Bio-Layer Interferometry) studies.

Shipping: Shipped at ambient temperature. Lyophilized protein is stable during transit.

Storage: Store lyophilized protein at -20°C to -80°C. Reconstituted protein should be aliquoted and stored at -80°C. Avoid repeated freeze-thaw cycles.

Shelf Life: 12 months from date of receipt when stored as recommended.

Shipping Time: Orders placed before 2 PM EST ship same day. International orders typically deliver within 5-10 business days.

Protein Biology

Function

Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake (PubMed:10227690, PubMed:10954735, PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:32860739). Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses (PubMed:18245775, PubMed:19449892). Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative transport of glucose into the brain (PubMed:10227690). In association with BSG and NXNL1, promotes retinal cone survival by increasing glucose uptake into photoreceptors (By similarity). Required for mesendoderm differentiation (By similarity)

Subcellular Location

Cell membrane (Multi-pass membrane protein); Melanosome; Photoreceptor inner segment

Disease Association

GLUT1 deficiency syndrome 1 (GLUT1DS1) : A neurologic disorder showing wide phenotypic variability. The most severe 'classic' phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor incoordination, and spasticity. Onset of seizures, usually characterized by apneic episodes, staring spells, and episodic eye movements, occurs within the first 4 months of life. Other paroxysmal findings include intermittent ataxia, confusion, lethargy, sleep disturbance, and headache. Varying degrees of cognitive impairment can occur, ranging from learning disabilities to severe intellectual disability. [The disease is caused by variants affecting the gene represented in this entry] | GLUT1 deficiency syndrome 2 (GLUT1DS2) : A clinically variable disorder characterized primarily by onset in childhood of paroxysmal exercise-induced dyskinesia. The dyskinesia involves transient abnormal involuntary movements, such as dystonia and choreoathetosis, induced by exercise or exertion, and affecting the exercised limbs. Some patients may also have epilepsy, most commonly childhood absence epilepsy. Mild intellectual disability may also occur. In some patients involuntary exertion-induced dystonic, choreoathetotic, and ballistic movements may be associated with macrocytic hemolytic anemia. [The disease is caused by variants affecting the gene represented in this entry] | Epilepsy, idiopathic generalized 12 (EIG12) : A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain. Seizure types include juvenile myoclonic seizures, absence seizures, and generalized tonic-clonic seizures. In some EIG12 patients seizures may remit with age. [Disease susceptibility is associated with variants affecting the gene represented in this entry] | Dystonia 9 (DYT9) : An autosomal dominant neurologic disorder characterized by childhood onset of paroxysmal choreoathetosis and progressive spastic paraplegia. Most patients show some degree of cognitive impairment. Other variable features may include seizures, migraine headaches, and ataxia. [The disease is caused by variants affecting the gene represented in this entry] | Stomatin-deficient cryohydrocytosis with neurologic defects (SDCHCN) : A rare form of stomatocytosis characterized by episodic hemolytic anemia, cold-induced red cells cation leak, erratic hyperkalemia, neonatal hyperbilirubinemia, hepatosplenomegaly, cataracts, seizures, intellectual disability, and movement disorder. [The disease is caused by variants affecting the gene represented in this entry]

Tissue Specificity

Detected in erythrocytes (at protein level). Expressed at variable levels in many human tissues

Subunit

Interacts with GIPC (via PDZ domain) (By similarity). Found in a complex with ADD2, DMTN and SLC2A1. Interacts (via C-terminus cytoplasmic region) with DMTN isoform 2 (PubMed:18347014). Interacts with SNX27; the interaction is required when endocytosed to prevent degradation in lysosomes and promote recycling to the plasma membrane (PubMed:23563491). Interacts with STOM (PubMed:23219802). Interacts with SGTA (via Gln-rich region) (By similarity). Interacts with isoform 1 of BSG (PubMed:25957687)

Pathway

Carbohydrate degradation

Gene: SLC2A1  |  Organism: Homo sapiens  |  Synonyms: Glucose transporter type 1, erythrocyte/brain; HepG2 glucose transporter
Key Publications

Frequently Asked Questions

How do I order or inquire about this product?

Fill out the Online Inquiry form with your required quantity and specifications. You can also email sales@biocrestsci.com. Our team typically responds within 4 business hours with a quote and availability confirmation.

What is the shipping and delivery time?

Orders placed before 2 PM EST ship the same day. Domestic (US) delivery typically takes 2-3 business days. International orders deliver within 5-10 business days. All products are shipped at ambient temperature with appropriate packaging to ensure stability.

How should I store this recombinant protein?

Lyophilized proteins should be stored at -20°C to -80°C upon receipt. After reconstitution, aliquot and store at -80°C. Avoid repeated freeze-thaw cycles. Shelf life is 12 months from date of receipt when stored as recommended.

What quality controls are performed on your products?

Each product undergoes SDS-PAGE purity analysis (typically >85-95%), endotoxin testing, and bioactivity validation. Products are validated for ELISA, Western Blot, and SPR/BLI applications as specified on this product page. A Certificate of Analysis (CoA) is available upon request.

Shopping Cart
Scroll to Top